1. Delta Np63 alpha expression is regulated by the phosphoinositide 3-kinase pathway. Barbieri CE, Barton CE, Pietenpol JA (2003) J Biol Chem 278(51): 51408-14
    › Primary publication · 14555649 (PubMed)
  2. Combined modality management of breast cancer: development of predictive markers through proteomics. Chakravarthy B, Pietenpol JA (2003) Semin Oncol 30(4 Suppl 9): 23-36
    › Primary publication · 12908134 (PubMed)
  3. Cell cycle-dependent transduction of cell-permeant Cre recombinase proteins. Jo D, Lin Q, Nashabi A, Mays DJ, Unutmaz D, Pietenpol JA, Ruley HE (2003) J Cell Biochem 89(4): 674-87
    › Primary publication · 12858334 (PubMed)
  4. Analysis of cell-cycle checkpoint pathways in head and neck cancer cell lines: implications for therapeutic strategies. Coleman SC, Stewart ZA, Day TA, Netterville JL, Burkey BB, Pietenpol JA (2002) Arch Otolaryngol Head Neck Surg 128(2): 167-76
    › Primary publication · 11843726 (PubMed)
  5. Syk: a new player in the field of breast cancer. Stewart ZA, Pietenpol JA (2001) Breast Cancer Res 3(1): 5-7
    › Primary publication · 11250739 (PubMed) · PMC138668 (PubMed Central)
  6. p53 Signaling and cell cycle checkpoints. Stewart ZA, Pietenpol JA (2001) Chem Res Toxicol 14(3): 243-63
    › Primary publication · 11258974 (PubMed)
  7. Kinetics of p53 binding to promoter sites in vivo. Szak ST, Mays D, Pietenpol JA (2001) Mol Cell Biol 21(10): 3375-86
    › Primary publication · 11313463 (PubMed) · PMC100259 (PubMed Central)
  8. Increased p53 phosphorylation after microtubule disruption is mediated in a microtubule inhibitor- and cell-specific manner. Stewart ZA, Tang LJ, Pietenpol JA (2001) Oncogene 20(1): 113-24
    › Primary publication · 11244509 (PubMed)
  9. Development and implementation of a science training course for breast cancer activists: Project LEAD (leadership, education and advocacy development). Dickersin K, Braun L, Mead M, Millikan R, Wu AM, Pietenpol J, Troyan S, Anderson B, Visco F (2001) Health Expect 4(4): 213-20
    › Primary publication · 11703495 (PubMed) · PMC5060083 (PubMed Central)
  10. A-204197, a new tubulin-binding agent with antimitotic activity in tumor cell lines resistant to known microtubule inhibitors. Tahir SK, Han EK, Credo B, Jae HS, Pietenpol JA, Scatena CD, Wu-Wong JR, Frost D, Sham H, Rosenberg SH, Ng SC (2001) Cancer Res 61(14): 5480-5
    › Primary publication · 11454695 (PubMed)